肝硬化治療市場規模、佔有率和成長分析（按疾病類型、治療類型、最終用戶和地區）- 行業預測，2025-2032 年

2023 年全球肝硬化治療市場規模價值 177.6 億美元，預計將從 2024 年的 189 億美元成長到 2032 年的 310.4 億美元，預測期內（2025-2032 年）的複合年成長率為 6.4%。

肝硬化的特徵是嚴重的肝損傷和瘢痕形成，是全球主要的健康威脅，特別是考慮到隨著生活方式的改變而導致的肝病盛行率日益增加。肝硬化治療市場成長的主要驅動力包括慢性肝病盛行率的上升，目前影響全球約15億人，以及酒精消費量的增加和不良的飲食習慣。特別是非酒精性脂肪肝病 (NAFLD) 已成為主要原因，預計到 2040 年將達到 55.7%。此外，B型肝炎和C型肝炎仍然是一個嚴重的問題，因為它們會加劇肝硬化和肝細胞癌的風險，導致大量死亡。因此，各大製藥公司均致力於開發治療肝病的有效藥物。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

肝硬化治療市場規模（依疾病類型及複合年成長率）（2025-2032）

• 市場概況
• 酒精性肝硬化
• 萎縮性肝硬化
• 膽汁性肝硬化
• 原因不明的肝硬化

肝硬化治療市場規模（按治療類型和複合年成長率） (2025-2032)

• 市場概況
• 免疫抑制劑
• 抗生素
• 疫苗
• 抗病毒藥物
• 皮質類固醇

肝硬化治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 其他

肝硬化治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Gilead Sciences（United States）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca（United Kingdom）
• Bayer AG（Germany）
• Sanofi（France）
• AbbVie Inc.（United States）
• GlaxoSmithKline PLC（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Alnylam Pharmaceuticals Inc.（United States）
• Viking Therapeutics（United States）
• Galectin Therapeutics Inc.（United States）
• Akero Therapeutics, Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Poxel SA（France）

結論和建議

Global Liver Cirrhosis Treatment Market size was valued at USD 17.76 billion in 2023 and is poised to grow from USD 18.9 billion in 2024 to USD 31.04 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

Cirrhosis of the liver, marked by significant liver damage and scarring, poses a major global health threat, especially given the rising prevalence of liver diseases linked to lifestyle changes. Key drivers for the growth of the liver cirrhosis treatment market include the escalating incidence of chronic liver diseases, which currently affect approximately 1.5 billion people worldwide, along with increasing alcohol consumption and poor dietary habits. Notably, non-alcoholic fatty liver disease (NAFLD) is emerging as the leading cause, with projections indicating its prevalence could reach 55.7% by 2040. Additionally, hepatitis B and C remain critical concerns, exacerbating the risk of cirrhosis and hepatocellular carcinoma, resulting in substantial mortality rates. Consequently, major pharmaceutical companies are intensifying their efforts to develop effective liver disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cirrhosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cirrhosis Treatment Market Segmental Analysis

Global Liver Cirrhosis Treatment Market is segmented by Disease Type, Treatment Type, End User and region. Based on Disease Type, the market is segmented into Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis and Cryptogenic Cirrhosis. Based on Treatment Type, the market is segmented into Immunosuppressants, Antibiotics, Vaccines, Anti-viral drugs and Corticosteroids. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cirrhosis Treatment Market

The global liver cirrhosis treatment market is being significantly driven by the rising prevalence of liver diseases worldwide. Factors such as sedentary lifestyles, poor dietary choices, and the aging population have contributed to this increase. Additionally, the prevalence of autoimmune conditions like hepatitis and non-alcoholic fatty liver disease is also rising. Alcohol consumption further exacerbates liver health issues. The increased demand for effective hepatitis treatments has prompted healthcare organizations to invest in the development of innovative drugs, devices, and therapies, bolstered by support from biotechnology firms and research institutions. This competitive landscape is poised to create substantial growth opportunities for market participants, ensuring a prosperous future for the liver disease treatment sector.

Restraints in the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market faces several restraints that hinder its growth trajectory. One of the primary challenges is the high cost associated with drugs, procedures, and surgeries needed to manage liver diseases, which significantly impacts market expansion. Additionally, inadequate healthcare services, particularly in rural or underserved regions, coupled with a lack of awareness regarding liver diseases and their symptoms among both the general public and healthcare professionals, further exacerbate the issue. Moreover, societal stigma surrounding certain liver conditions, such as those resulting from bacterial infections or alcohol, complicates treatment accessibility. Difficulties in liver transplantation, strict regulatory frameworks, and a scarcity of effective drugs under research and development also impede market progress, as substantial financial resources are necessary for treatment.

Market Trends of the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market is poised for significant growth, driven by elevated research and development investments focusing on innovative therapies and targeted treatments for liver diseases. With a burgeoning awareness of liver health, enhanced healthcare services, and increased funding for prevention and diagnosis, the landscape is improving markedly. Furthermore, the aging population and rising disposable incomes in emerging markets are catalyzing demand for sophisticated healthcare solutions. Advances in surgical procedures and radiological interventions are also facilitating better treatment options, collectively propelling the market towards expansion and efficiency in managing liver cirrhosis and associated conditions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Liver Cirrhosis Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Alcoholic Cirrhosis
• Atrophic Cirrhosis
• Biliary Cirrhosis
• Cryptogenic Cirrhosis

Global Liver Cirrhosis Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Immunosuppressants
• Antibiotics
• Vaccines
• Anti-viral drugs
• Corticosteroids

Global Liver Cirrhosis Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Other

Global Liver Cirrhosis Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galectin Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poxel SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations